Deramiocel’s 9 to 3 FDA panel defeat wipes out half of Capricor’s value before August decision

Capricor Therapeutics, Inc. (Nasdaq: CAPR) lost roughly half of its remaining market value after an FDA advisory committee voted 9 to 3 that the HOPE-3 trial did not provide substantial evidence that deramiocel effectively treats cardiomyopathy in male patients with Duchenne muscular dystrophy. Capricor shares traded near $3.27 late Thursday morning, after touching an intraday low around $2.50, leaving the company with a market capitalization of approximately $188 million. The stock had already fallen sharply after FDA briefing documents questioned the trial population, missing data and changes to the statistical analysis. The advisory vote is nonbinding, and the agency’s final decision remains scheduled for August 22, 2026. The central business issue is whether the FDA can look beyond the panel’s objections and approve a product tied to an $80 million milestone, substantial future revenue sharing and more than $100 million of commercialization spending.

Why the 9 to 3 deramiocel vote destroyed Capricor’s remaining regulatory premium

The advisory committee was asked a deliberately narrow question: whether HOPE-3 provided substantial evidence that deramiocel is effective for the proposed indication of treating cardiomyopathy in Duchenne muscular dystrophy. Nine members voted no and three voted yes. FDA advisory committees provide independent recommendations that are not legally binding, although the agency generally gives their conclusions considerable weight.

The negative vote matters because Capricor’s value has been overwhelmingly tied to deramiocel becoming its first approved commercial product. The company currently has no approved medicines and stated in its first-quarter filing that its ability to generate product revenue and become profitable depends on the successful approval and commercialization of deramiocel and future candidates.

FDA reviewers did not reject the possibility that deramiocel has biological activity. Their concerns centered on whether the submitted evidence reliably demonstrated benefit for the cardiac condition named in the proposed label.

HOPE-3 enrolled 106 participants and measured upper-limb function through the Performance of the Upper Limb 2.0 assessment as its primary endpoint. Capricor’s final analysis reported a statistically significant benefit in upper-limb function and supportive cardiac findings. The company argues that its final statistical plan was completed before the study was unblinded and that earlier analyses cited by FDA reviewers were obsolete drafts that did not reflect the completed study.

The FDA took a more skeptical position. Reviewers said the apparent significance of the upper-limb result changed materially depending on the analysis method, treatment of missing data and handling of influential participants. They also questioned whether the cardiac result was robust when evaluated using earlier prespecified assumptions.

The proposed indication created an additional weakness. HOPE-3 was conducted in people with Duchenne muscular dystrophy, but the FDA questioned whether the participants consistently had established cardiomyopathy at enrollment. Mean baseline heart-pumping function was relatively preserved, and the trial’s main endpoint evaluated arm and hand function rather than a direct clinical measure of cardiac disease.

That mismatch gave panel members a reason to separate deramiocel’s possible skeletal-muscle benefit from the evidence required for a cardiomyopathy label. A statistically persuasive upper-limb result could still be meaningful for non-ambulatory patients, but it does not automatically prove that the therapy slows heart disease.

The market response reflects the probability shift rather than a final regulatory outcome. Capricor’s market value stood near $380 million at Wednesday’s close and fell toward $188 million during Thursday trading. The stock had already lost more than two-thirds of its value following publication of the FDA briefing documents, meaning the panel vote removed much of the remaining expectation that the agency would approve deramiocel without another trial.

An August approval could unlock $80 million, but Capricor’s launch partner is now in court

FDA approval would create an immediate financial catalyst under Capricor’s United States commercialization agreement with Nippon Shinyaku. The agreement provides for an additional $80 million development milestone upon United States marketing approval. It also includes potential sales milestones tied to annual net sales of up to $605 million and gives Capricor a share of product revenue ranging between 30% and 50%.

Those economics once gave Capricor a relatively capital-efficient commercialization model. Capricor was responsible for clinical development and manufacturing, while Nippon Shinyaku and its United States subsidiary, NS Pharma, were expected to manage distribution. The structure allowed Capricor to preserve a substantial share of product economics without building every element of a commercial organization internally.

That relationship is now the subject of litigation. Capricor filed a complaint in New Jersey in May seeking to rescind the United States distribution agreement or obtain the right to commercialize deramiocel directly or through another distributor. The company alleges that the agreement contains a fundamental pricing flaw and that Nippon Shinyaku and NS Pharma failed to prepare adequately for a launch. These are Capricor’s allegations and have not been established by a final court judgment.

Capricor’s complaint claims the agreement’s pricing formula interacts with Medicare reimbursement in a way that could make production, distribution and administration economically unviable. It also alleges that the distributor did not complete an acceptable gross-to-net model, establish a realistic wholesale price or perform adequate mock-launch exercises. Nippon Shinyaku and NS Pharma may dispute those allegations or assert counterclaims.

The legal dispute means FDA approval would not automatically produce a smooth commercial launch. Capricor could receive the $80 million approval milestone under the existing agreement, depending on contractual obligations and litigation outcomes, but the company is simultaneously trying to exit or restructure the arrangement governing United States distribution.

Capricor has acknowledged that litigation may continue for an extended period, consume management resources and impair its ability to commercialize deramiocel. Even if the company obtains the relief it seeks, it has no experience launching an FDA-approved product at commercial scale and may need to secure a replacement distributor or create additional internal capabilities.

The international position is also less developed than the United States opportunity. The Japan agreement provides for approximately $89 million in potential development and sales milestones and a meaningful double-digit share of product revenue, but Capricor was still evaluating the Japanese regulatory pathway at the end of March.

A proposed European arrangement has not progressed. Capricor’s amended European term sheet with Nippon Shinyaku expired on April 1, 2026, without a definitive agreement, and the company had not received consideration or recognized revenue from it as of March 31.

The commercial value at risk therefore extends beyond the United States approval decision. Deramiocel must clear the FDA, resolve or work around the distributor dispute, establish a viable reimbursement structure and then support separate regulatory strategies in Japan and Europe.

Capricor’s $278.6 million cash balance limits immediate financing pressure but not execution risk

Capricor reported $278.6 million in cash, cash equivalents and marketable securities at March 31, 2026. That amount exceeded the company’s approximately $188 million intraday market capitalization on July 30. The comparison suggests the market was assigning a negative value to expected development spending, legal uncertainty and the risk-adjusted pipeline after accounting for the last reported financial assets.

The cash comparison requires caution. Capricor has continued spending since March, and its balance sheet included approximately $47.6 million in liabilities, including lease obligations, accrued expenses, deferred revenue and a California Institute for Regenerative Medicine liability. Last reported cash cannot be treated as immediately distributable value.

The company used approximately $29.3 million in operating cash during the first quarter, compared with $6.4 million a year earlier. Its quarterly net loss rose to $33.9 million from $24.4 million as manufacturing, regulatory and commercialization preparations expanded.

Capricor expected to spend approximately $100 million to $125 million on the deramiocel program during 2026. That estimate included manufacturing expansion, product inventory, clinical activities, regulatory work and pre-commercial preparation. Approval could convert part of that spending into launch inventory and infrastructure, while rejection could force the company to reconsider how much additional capital should be committed before regulatory uncertainty is resolved.

The balance sheet gives Capricor time to respond to an unfavorable decision without immediately returning to capital markets. Management stated that its March resources were sufficient to fund operations for at least 12 months after issuance of the first-quarter financial statements.

The stock collapse could still reshape capital allocation. Raising equity near $3 per share would create far more dilution than financing when the stock traded above $20 earlier in July. Capricor has an at-the-market equity program, but using it aggressively after the decline would expand the share count at a depressed valuation.

If the FDA issues another Complete Response Letter and requires a new prospective trial focused on confirmed cardiomyopathy, the company may need to fund several more years of clinical work without product revenue. A longer study centered on cardiac progression could require substantial enrollment, repeated imaging and extended follow-up because Duchenne-related heart deterioration develops gradually.

The cash balance reduces the risk that one negative decision ends the company. It does not protect shareholders from value destruction if Capricor must finance another pivotal program, rebuild its commercialization strategy and continue litigation while the stock remains below last reported cash per share.

What the FDA can still decide before deramiocel’s August 22 action date

The FDA is not required to follow the advisory committee. The agency will assess the full application, including clinical data, statistical analyses, manufacturing information, safety findings and the severity of unmet need in Duchenne muscular dystrophy. There is no approved therapy specifically demonstrated to alter Duchenne cardiomyopathy progression, which gives deramiocel a clinically important target if its effect can be established reliably.

Full approval on August 22 remains possible, but the negative vote makes it a more difficult outcome. The FDA would need to conclude that the total evidence is persuasive despite the panel’s concerns about patient selection, analytical sensitivity and the relationship between the strongest functional result and the proposed cardiac indication.

The agency could approve a narrower population or impose post-marketing requirements. Such an approach might focus on patients with specific baseline cardiac characteristics or require additional confirmatory evidence after launch. Whether the submitted application and available data support a narrower label is not publicly established.

Another Complete Response Letter may be more likely after the vote. The FDA could request a trial that prospectively enrolls patients with clearly defined Duchenne cardiomyopathy and uses a locked statistical plan with direct cardiac endpoints. That would address the committee’s central objections but substantially delay revenue and increase costs.

The agency could also determine that the upper-limb findings warrant a separate development or regulatory strategy. Capricor has emphasized that the panel discussion appeared more favorable toward preservation of arm and hand function, but the formal voting question did not evaluate approval for that use. A different indication could require amendments, additional analyses or another submission rather than an immediate change to the current label.

Manufacturing readiness will remain relevant under any positive outcome. Deramiocel is an allogeneic cell product produced from donor heart-derived cells and administered by intravenous infusion approximately every three months. Commercial supply requires consistent cell expansion, potency testing, cryogenic handling and distribution to treatment centers.

The advisory committee did not eliminate deramiocel’s potential value, but it changed the burden of proof. Capricor must now persuade the FDA that the totality of evidence supports approval after independent experts concluded that the pivotal trial did not establish effectiveness for the proposed cardiomyopathy indication.

The August decision will determine whether the July collapse represents an excessive reaction to a nonbinding vote or an early recognition that another lengthy clinical program lies ahead. Even an approval would leave Capricor with major commercial questions involving reimbursement, its distributor lawsuit and the economics of repeated cell-therapy manufacturing.

Key takeaways from the deramiocel panel vote and Capricor’s investment outlook

• The FDA advisory committee voted 9 to 3 that HOPE-3 did not provide substantial evidence that deramiocel effectively treats Duchenne cardiomyopathy.
• Capricor’s market capitalization fell from approximately $380 million at Wednesday’s close to about $188 million during Thursday trading, after the stock had already dropped sharply on the FDA briefing documents.
• The vote is nonbinding, and the FDA’s final action date remains August 22, 2026, leaving approval possible but materially less certain.
• FDA reviewers questioned whether HOPE-3 consistently enrolled patients with established cardiomyopathy and whether altered statistical methods produced robust efficacy findings.
• Capricor argues that its final analysis plan was completed before unblinding and that deramiocel produced statistically significant skeletal and cardiac benefits.
• United States approval could trigger an $80 million milestone from Nippon Shinyaku and support future sales milestones and a 30% to 50% share of product revenue.
• Capricor is suing Nippon Shinyaku and NS Pharma over alleged pricing and launch-preparation failures, creating commercial uncertainty even if deramiocel is approved.
• Last reported cash and investments of $278.6 million exceeded Capricor’s July 30 market value, but operating spending, liabilities and potential additional trials reduce the significance of that comparison.
• Capricor expects to spend $100 million to $125 million on deramiocel during 2026, including manufacturing expansion, inventory and launch preparation.
• Another FDA rejection could require a new cardiomyopathy-focused trial and expose shareholders to further delay, spending and dilution at a much lower stock price.